Neurocrine Biosciences Inc (NBIX) Stock Analysis

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $130.64
• Market Cap: $13.16B
• P/E Ratio: 28.02
• EPS: $4.68
• 52-Week High: $160.18
• 52-Week Low: $84.23

Market Sentiment

Neurocrine Biosciences Inc currently has a Bullish sentiment score of 0.23.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. (NBIX), based in San Diego, California, is a leading biopharmaceutical company specializing in the development of innovative treatments for neurological, endocrine, and psychiatric disorders. The company boasts a robust pipeline, including advanced therapies targeting Parkinson's disease, epilepsy, and various other serious medical conditions, addressing critical unmet needs in patient care. Neurocrine's commitment to scientific excellence and strategic partnershi...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Neurocrine Biosciences Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does NBIX pay dividends?

Neurocrine Biosciences Inc (NBIX) does not currently pay a regular dividend.

What is NBIX's P/E ratio?

Neurocrine Biosciences Inc has a price-to-earnings (P/E) ratio of 28.02.

What is NBIX's market cap?

Neurocrine Biosciences Inc (NBIX) has a market capitalization of $13.16B with a current stock price of $130.64.